Arrowhead climbs as traders buy ahead of May 7 earnings and EU Redemplo momentum
ARWR•Arrowhead Pharmaceuticals (ARWR) is higher on May 6, 2026 as investors position ahead of the company’s fiscal Q2 2026 results call scheduled for May 7, 2026. The stock is also riding renewed optimism around Redemplo (plozasiran) following a recent positive CHMP opinion in Europe dated April 23, 2026.
1) What’s moving ARWR today
Arrowhead Pharmaceuticals shares are moving higher on May 6, 2026 with a classic “ahead of earnings” setup: the company is scheduled to host its fiscal 2026 second-quarter results webcast and conference call on May 7, 2026 at 4:30 p.m. ET. With a biotech name that has a key commercial launch underway and multiple late-stage pipeline milestones, incremental buying into the print can be enough to push the stock several percent on no incremental same-day headline.
2) Redemplo momentum adds a fundamental tailwind
Beyond the calendar catalyst, sentiment has been supported by recent regulatory momentum for Redemplo (plozasiran). On April 23, 2026, the EMA’s CHMP adopted a positive opinion recommending marketing authorization for Redemplo for adults with familial chylomicronaemia syndrome (FCS), a step that often precedes a formal European Commission decision. That backdrop can lift expectations that Arrowhead’s first commercial product expands beyond the U.S. while the company continues to pursue larger hypertriglyceridemia opportunities.
3) What investors will listen for on May 7
On the May 7 call, investors typically focus on (1) early launch indicators for Redemplo (patient starts, payer coverage, and commercial infrastructure buildout), (2) updated timelines for plozasiran’s broader Phase 3 program and any planned supplemental filing strategy, and (3) cash runway and spending cadence. Any new color on 2026 catalysts and commercialization execution could be the difference between a “sell-the-news” reaction and a follow-through move.
